Trial Information

Summary: A Phase I Study of Alefacept (Amevive) in the Treatment of Cutaneous-T-Cell Lymphoma and Peripheral T-Cell NHL

You have been asked to participate in this research study because you have been diagnosed with Cutaneous T-cell Lymphoma (CTCL) or peripheral T-cell Non-Hodgkin’s Lymphoma (NHL).  The purpose of this research study is to determine the highest possible dose of the investigational drug Alefacept (Amevive ^TM) that can be given to subjects with CTCL or peripheral T-Cell NHL before unmanageable side effects are seen.  The study will also collect information on response of these cancers to Alefacept (Amevive ^TM).  Your participation in this study is expected to last one year for treatment.  After your treatment on this study is over, your medical condition will be followed every three months up to 3 years.

Patient Inclusion/Exclusion Criteria:

- See http://clinicaltrials.coh.org for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: December 1, 2008 at 3:15:47 PM